LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fecal Hemoglobin Concentrations Varies with Gender and Age

By LabMedica International staff writers
Posted on 05 Jul 2012
Print article
Estimation of fecal hemoglobin concentration by fecal immunochemical tests (FIT) are becoming widely used in colorectal cancer screening.

Risk stratification is based on the concentration of the hemoglobin in the stool specimens and this helps clinicians make the subsequent decisions for diagnosis and treatment of colorectal neoplasia.

Scientists at the University of Dundee (UK) carried out a large observational study by making a single estimate of fecal hemoglobin concentration using quantitative automated immunoturbidimetry. From July 1, 2010, to January 12, 2011, all eligible men and women aged between 50 and 74 years resident in two of the 14 National Health Service Boards in Scotland were invited to participate. To investigate potential reference values, those who returned a testable fecal sample were defined as the reference population. No exclusion criteria were applied.

The reference sample group comprised of 38,720 in total, including 18,058 men (46.6 %) and 20,662 women (53.4 %) who returned a testable sample. The potential upper reference limits, were 519 ng hemoglobin/mL (90% Confidence Interval (CI): 468-575) for men and 283 ng hemoglobin/mL (90% CI: 257-316) for women. The concentration of hemoglobin increased with age in both genders. The decision limits have advantages over the reference intervals. At any cut-off concentration, more men are declared positive than women and more older people are declared positive than younger people. Future risk of neoplasia is higher in men than in women and in older people.

The authors concluded that that the truly healthy individual has no detectable fecal hemoglobin by conventional quantitative methodology and that any hemoglobin present is unusual. Fecal hemoglobin concentrations vary with gender and age and should be included in individual risk assessment scores. They suggest that more tailored strategies are needed in colorectal cancer screening programs. The study was published on May 25, 2012, in the journal Clinical Chemistry and Laboratory Medicine.

Related Links:

University of Dundee


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more